Head-to-head · free

Becton, Dickinson and Company vs BioStem Technologies, Inc.

BDX vs BSEM — return on capital, cash generation, margins and balance sheet side by side.

BDX

0 / 0

measures where BDX leads

BSEM

0 / 0

measures where BSEM leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureBDX · FY2025BSEM
Revenue$21.8B—
Net income$1.7B—
Revenue growth (yearly, multi-year)1.9%—
Free cash flow——
Free cash flow margin——
Net cash / (debt)——
ROIC5.1%—
Return on equity6.5%—
Gross margin45.4%—
Operating margin13.7%—
Net debt / EBITDA3.68x—

Figures are as reported by each company; latest fiscal year shown.

Where Becton, Dickinson and Company's cash went (FY2025)

Capital spending
$760.0M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full BDX profile →

Where BioStem Technologies, Inc.'s cash went

Not reported yet.

Full BSEM profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons